Sang Kyum Kim

Yonsei University

H指数:27

被引数:3,264

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Synthesized Depside Molecules Suppress the Progression of Colorectal Cancer by Binding VDAC1/PHB/MMP9 Being at the Crossroads of Stemness, Motility, Apoptosis, and Metabolism

合成的 depside 分子通过结合 VDAC1/PHB/MMP9 抑制结直肠癌的进展，该复合物位于干性、迁移、凋亡和代谢的交叉路口。

MedComm

IF10.7

2025-10-310

OAAI

Targeted Nanocomplex Delivery for Protecting Vascular Integrity and Enhancing Anticancer Effects in Hepatocellular Carcinoma

靶向纳米复合物递送以保护血管完整性并增强肝癌的抗癌效果

Small Science

IF8.3

2025-07-250

OAAI

Enhancing toxicity prediction for natural products in herbal medicine and dietary supplements: Integrating (Q)STR models and in vitro assays

TOXICOLOGY AND APPLIED PHARMACOLOGY

IF3.4

2025-02-010

PRE

Prediction of Bone Marrow Metastases Using Computed Tomography (CT) Radiomics in Patients with Gastric Cancer: Uncovering Invisible Metastases

DIAGNOSTICS

IF3.3

2024-08-051

OAAI

Nuclear Localization of Yes-Associated Protein is Associated With Tumor Progression in Cutaneous Melanoma

LABORATORY INVESTIGATION

IF4.2

2024-05-010

OAAI

Overcoming BRAF and CDK4/6 inhibitor resistance by inhibiting MAP3K3-dependent protection against YAP lysosomal degradation

EXPERIMENTAL AND MOLECULAR MEDICINE

IF12.9

2024-04-160

OAAI

Hepa-ToxMOA: a pathway-screening method for evaluating cellular stress and hepatic metabolic-dependent toxicity of natural products

SCIENTIFIC REPORTS

IF3.9

2024-02-211

OAAI

Clinical Activity of TGF-β Inhibitor Vactosertib in Combination with Imatinib in Desmoid Tumors: A Multicenter Phase Ib/II Study

CLINICAL CANCER RESEARCH

IF10.2

2024-02-163

PRE

Durvalumab plus pazopanib combination in patients with advanced soft tissue sarcomas: a phase II trial

Durvalumab联合帕唑帕尼治疗晚期软组织肉瘤的II期临床试验

NATURE COMMUNICATIONS

IF15.7

2024-01-237

OAAI

Genomic and transcriptomic profiling reveal molecular characteristics of parathyroid carcinoma

EXPERIMENTAL AND MOLECULAR MEDICINE

IF12.9

2023-05-014

OAAI

Comprehensive molecular characterization of clinical response to durvalumab plus pazopanib combination in patients with advanced soft tissue sarcomas: A phase 2 clinical trial

CANCER RESEARCH

IF16.6

2023-04-141

PRE

YAP inhibition via targeting MAP3K3-dependent lysosomal degradation pathway overcomes BRAF and CDK4/6 inhibitor resistance

CANCER RESEARCH

IF16.6

2023-04-040

PRE

A nomogram combining clinical factors and biomarkers for predicting the recurrence of high-risk cutaneous squamous cell carcinoma

BMC CANCER

IF3.4

2022-11-032

OAAI

First-line pembrolizumab versus dabrafenib/trametinib treatment for BRAF V600-mutant advanced melanoma

一线pembrolizumab与dabrafenib/trametinib治疗BRAF V600-mutant晚期黑色素瘤

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

IF11.8

2022-11-012

PRE

Phase II Clinical Trial of Eribulin-Gemcitabine Combination Therapy in Previously Treated Patients With Advanced Liposarcoma or Leiomyosarcoma

CLINICAL CANCER RESEARCH

IF10.2

2022-05-185

Diagnostic Utility of Somatostatin Receptor 2A Immunohistochemistry for Tumor-induced Osteomalacia

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

IF5.1

2022-02-201

Nevus Comedonicus Syndrome Associated with Psychiatric Disorder

DIAGNOSTICS

IF3.3

2022-02-020

OAAI

PD-L1 tumour expression is predictive of pazopanib response in soft tissue sarcoma

BMC CANCER

IF3.4

2021-03-315

OAAI

WWC1 and NF2 Prevent the Development of Intrahepatic Cholangiocarcinoma by Regulating YAP/TAZ Activity through LATS in Mice

WWC1和NF2通过小鼠LATS调节YAP/TAZ活性预防肝内胆管癌的发生

MOLECULES AND CELLS

IF6.5

2020-05-0121

PRE

YAP Activity is Not Associated with Survival of Uveal Melanoma Patients and Cell Lines

SCIENTIFIC REPORTS

IF3.9

2020-04-1015

OAAI

Sang Kyum Kim

个人简介

教育背景

工作经历

荣誉奖项

研究方向